BACKGROUND AND AIMS: Although both cancer and stellate cells (PSCs) secrete proangiogenic factors, pancreatic cancer is a scirrhous and hypoxic tumor. The impact of cancer-PSCs interactions on angiogenesis was analyzed. METHODS: Expression of periostin, CD31, and alpha-smooth muscle actin was assessed by immunohistochemistry. Human PSCs and cancer cells were cultivated under normoxia and hypoxia alone, or in coculture, to analyze the changes in their angiogenic and fibrogenic attributes, using enzyme-linked immunosorbent assay, immunoblot, and quantitative polymerase chain reaction analyses and growth of cultured endothelial cells in vitro. RESULTS: On the invasive front of the activated stroma, PSCs deposited a periostin-rich matrix around the capillaries in the periacinar spaces. Compared with the normal pancreas, there was a significant reduction in the microvessel density in chronic pancreatitis (five-fold, P < .001) and pancreatic cancer (four-fold, P < .01) tissues. In vitro, hypoxia increased PSCs' activity and doubled the secretion of periostin, type I collagen, fibronectin, and vascular endothelial growth factor (VEGF). Cancer cells induced VEGF secretion of PSCs (390 +/- 60%, P < .001), whereas PSCs increased the endostatin production of cancer cells (210 +/- 14%, P < .001) by matrix metalloproteinase-dependent cleavage. In vitro, PSCs increased the endothelial cell growth, whereas cancer cells alone, or their coculture with PSCs, suppressed it. CONCLUSIONS: Although PSCs are the dominant producers of VEGF and increase endothelial cell growth in vitro, in the peritumoral stroma, they contribute to the fibrotic/hypoxic milieu through abnormal extracellular matrix deposition and by amplifying endostatin production of cancer cells.
BACKGROUND AND AIMS: Although both cancer and stellate cells (PSCs) secrete proangiogenic factors, pancreatic cancer is a scirrhous and hypoxic tumor. The impact of cancer-PSCs interactions on angiogenesis was analyzed. METHODS: Expression of periostin, CD31, and alpha-smooth muscle actin was assessed by immunohistochemistry. Human PSCs and cancer cells were cultivated under normoxia and hypoxia alone, or in coculture, to analyze the changes in their angiogenic and fibrogenic attributes, using enzyme-linked immunosorbent assay, immunoblot, and quantitative polymerase chain reaction analyses and growth of cultured endothelial cells in vitro. RESULTS: On the invasive front of the activated stroma, PSCs deposited a periostin-rich matrix around the capillaries in the periacinar spaces. Compared with the normal pancreas, there was a significant reduction in the microvessel density in chronic pancreatitis (five-fold, P < .001) and pancreatic cancer (four-fold, P < .01) tissues. In vitro, hypoxia increased PSCs' activity and doubled the secretion of periostin, type I collagen, fibronectin, and vascular endothelial growth factor (VEGF). Cancer cells induced VEGF secretion of PSCs (390 +/- 60%, P < .001), whereas PSCs increased the endostatin production of cancer cells (210 +/- 14%, P < .001) by matrix metalloproteinase-dependent cleavage. In vitro, PSCs increased the endothelial cell growth, whereas cancer cells alone, or their coculture with PSCs, suppressed it. CONCLUSIONS: Although PSCs are the dominant producers of VEGF and increase endothelial cell growth in vitro, in the peritumoral stroma, they contribute to the fibrotic/hypoxic milieu through abnormal extracellular matrix deposition and by amplifying endostatin production of cancer cells.
Authors: M V Apte; P S Haber; S J Darby; S C Rodgers; G W McCaughan; M A Korsten; R C Pirola; J S Wilson Journal: Gut Date: 1999-04 Impact factor: 23.059
Authors: L F Brown; A J Guidi; S J Schnitt; L Van De Water; M L Iruela-Arispe; T K Yeo; K Tognazzi; H F Dvorak Journal: Clin Cancer Res Date: 1999-05 Impact factor: 12.531
Authors: Max G Bachem; Marion Schünemann; Marco Ramadani; Marco Siech; Hans Beger; Andreas Buck; Shaoxia Zhou; Alexandra Schmid-Kotsas; Guido Adler Journal: Gastroenterology Date: 2005-04 Impact factor: 22.682
Authors: M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman Journal: Cell Date: 1997-01-24 Impact factor: 41.582
Authors: Mert Erkan; Jörg Kleeff; Irene Esposito; Thomas Giese; Knut Ketterer; Markus W Büchler; Nathalla A Giese; Helmut Friess Journal: Oncogene Date: 2005-06-23 Impact factor: 9.867
Authors: J Holash; P C Maisonpierre; D Compton; P Boland; C R Alexander; D Zagzag; G D Yancopoulos; S J Wiegand Journal: Science Date: 1999-06-18 Impact factor: 47.728
Authors: A Couvelard; D O'Toole; R Leek; H Turley; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella Journal: Histopathology Date: 2005-06 Impact factor: 5.087
Authors: Marco Dioguardi Burgio; Jérome Cros; Nicola Panvini; Thomas Depoilly; Anne Couvelard; Philippe Ruszniewski; Louis de Mestier; Olivia Hentic; Alain Sauvanet; Safi Dokmak; Alex Faccinetto; Maxime Ronot; Valérie Vilgrain Journal: Eur Radiol Date: 2021-05-11 Impact factor: 5.315
Authors: Giulia Grisendi; Rita Bussolari; Elena Veronesi; Serena Piccinno; Jorge S Burns; Giorgio De Santis; Pietro Loschi; Marco Pignatti; Fabrizio Di Benedetto; Roberto Ballarin; Carmela Di Gregorio; Valentina Guarneri; Lino Piccinini; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici Journal: Am J Cancer Res Date: 2011-05-28 Impact factor: 6.166
Authors: Mert Erkan; Nadine Weis; Zheng Pan; Christian Schwager; Tamar Samkharadze; Xiaohua Jiang; Ute Wirkner; Nathalia A Giese; Wilhelm Ansorge; Jürgen Debus; Peter E Huber; Helmut Friess; Amir Abdollahi; Jörg Kleeff Journal: Mol Cancer Date: 2010-04-23 Impact factor: 27.401